EU OK's Guidant's cobalt chromium coronary stent:
This article was originally published in Clinica
Executive Summary
Guidant has CE-marked for sale in Europe its first cobalt chromium stent platform for treating coronary artery disease. The Multi-Link Vision coronary stent system consists of thin struts and has shown "excellent" clinical results, with a nine-month clinically-driven target lesion revascularisation rate of 6.2%, says the firm. Guidant, which plans to use cobalt chromium stents in future stent and drug eluting stent platforms, says it expects to introduce a small-vessel cobalt chromium stent in Europe in the second quarter of 2003.